1. Home
  2. VATE vs CRDF Comparison

VATE vs CRDF Comparison

Compare VATE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo INNOVATE Corp.

VATE

INNOVATE Corp.

N/A

Current Price

$5.37

Market Cap

75.2M

Sector

Industrials

ML Signal

N/A

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

N/A

Current Price

$0.85

Market Cap

82.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VATE
CRDF
Founded
1994
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
75.2M
82.5M
IPO Year
1996
2012

Fundamental Metrics

Financial Performance
Metric
VATE
CRDF
Price
$5.37
$0.85
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
★ $6.28
AVG Volume (30 Days)
54.4K
★ 394.5K
Earning Date
11-16-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 27.37
EPS
N/A
★ N/A
Revenue
★ $1,246,000,000.00
$365,993.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$8.70
P/E Ratio
★ N/A
N/A
Revenue Growth
12.55
★ 49.61
52 Week Low
$3.75
$0.76
52 Week High
$21.30
$3.31

Technical Indicators

Market Signals
Indicator
VATE
CRDF
Relative Strength Index (RSI) 29.69 35.57
Support Level $5.35 $0.76
Resistance Level $5.56 $1.13
Average True Range (ATR) 0.36 0.08
MACD -0.01 -0.00
Stochastic Oscillator 4.02 23.79

Price Performance

Historical Comparison
VATE
CRDF

About VATE INNOVATE Corp.

Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

Share on Social Networks: